📊 CORZR Key Takeaways
Is Core Scientific, Inc./tx (CORZR) a Good Investment?
Core Scientific exhibits severe financial distress with negative stockholders' equity of -$962.7M, indicating liabilities exceed assets and shareholder value has been destroyed. The company burns through capital with negative free cash flow of -$450.8M despite generating $278.2M in operating cash flow, driven by unsustainable capital expenditures of $729M. Revenue declined 37.5% YoY while net losses widened to -$288.6M, demonstrating deteriorating operational performance across all profitability metrics.
Core Scientific's fundamentals remain very weak: revenue fell 37.5% year over year, gross margin is only 11.9%, and operating and net margins are deeply negative. While operating cash flow is positive and liquidity is adequate in the near term, the combination of negative equity, heavy losses, and extremely negative free cash flow points to poor financial health and low-quality growth.
Why Buy Core Scientific, Inc./tx Stock? CORZR Key Strengths
- Operating cash flow of $278.2M provides near-term liquidity buffer
- Current ratio of 1.15x indicates ability to cover short-term obligations
- Cash position of $311.4M offers runway for operations
- Positive operating cash flow of $278.25M indicates the core business still generates cash before capital spending
- Cash balance of $311.38M and current ratio of 1.15x provide some near-term liquidity support
- Diluted EPS improved year over year, suggesting losses per share narrowed despite continued net losses
CORZR Stock Risks: Core Scientific, Inc./tx Investment Risks
- Negative stockholders' equity of -$962.7M indicates potential insolvency; liabilities ($3.3B) far exceed assets ($2.3B)
- Massive negative free cash flow of -$450.8M is unsustainable; company burning $1.41 in cash for every dollar of revenue
- Revenue collapsed 37.5% YoY while operating losses expanded to -$245.6M, indicating operational model failure and deteriorating unit economics
- Capital expenditure of $729M is grossly disproportionate to revenue base, suggesting failed growth investments or impaired asset valuations
- Net margin of -90.5% and operating margin of -77.0% demonstrate fundamental business model dysfunction
- Negative stockholders' equity of $-962.74M signals a severely impaired balance sheet
- Operating margin of -77.0% and net margin of -90.5% show the business is structurally unprofitable
- Free cash flow of $-450.75M driven by very high capital expenditure creates ongoing financing risk
Key Metrics to Watch
- Operating cash flow trajectory and sustainability of $278.2M burn rate
- Cash depletion rate given negative FCF and current cash position of $311.4M
- Revenue stabilization and margin recovery toward positive operating income
- Capital expenditure reduction and asset utilization efficiency
- Debt restructuring or recapitalization necessity given negative equity position
- Sustained improvement in gross and operating margins
- Free cash flow trend relative to capital expenditure intensity
Core Scientific, Inc./tx (CORZR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Core Scientific, Inc./tx presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CORZR Profit Margin, ROE & Profitability Analysis
CORZR vs Finance Sector: How Core Scientific, Inc./tx Compares
How Core Scientific, Inc./tx compares to Finance sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Core Scientific, Inc./tx Stock Overvalued? CORZR Valuation Analysis 2026
Based on fundamental analysis, Core Scientific, Inc./tx has mixed fundamental signals relative to the Finance sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Core Scientific, Inc./tx Balance Sheet: CORZR Debt, Cash & Liquidity
CORZR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Core Scientific, Inc./tx's revenue has declined by 20% over the 5-year period, indicating business contraction. The most recent EPS of $-0.65 indicates the company is currently unprofitable.
CORZR Revenue Growth, EPS Growth & YoY Performance
CORZR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $81.1M | -$146.7M | $-0.46 |
| Q2 2025 | $78.6M | -$356.1M | $-0.04 |
| Q1 2025 | $79.5M | $210.7M | $0.78 |
| Q3 2024 | $95.4M | -$41.1M | $-0.11 |
| Q2 2024 | $126.9M | -$9.3M | $-0.02 |
| Q1 2024 | $120.7M | -$388.0K | $0.00 |
| Q3 2023 | $112.9M | -$388.0K | $0.00 |
| Q2 2023 | $126.9M | -$388.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Core Scientific, Inc./tx Dividends, Buybacks & Capital Allocation
CORZR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Core Scientific, Inc./tx (CIK: 0001839341)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CORZR
What is the AI rating for CORZR?
Core Scientific, Inc./tx (CORZR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CORZR's key strengths?
Claude: Operating cash flow of $278.2M provides near-term liquidity buffer. Current ratio of 1.15x indicates ability to cover short-term obligations. ChatGPT: Positive operating cash flow of $278.25M indicates the core business still generates cash before capital spending. Cash balance of $311.38M and current ratio of 1.15x provide some near-term liquidity support.
What are the risks of investing in CORZR?
Claude: Negative stockholders' equity of -$962.7M indicates potential insolvency; liabilities ($3.3B) far exceed assets ($2.3B). Massive negative free cash flow of -$450.8M is unsustainable; company burning $1.41 in cash for every dollar of revenue. ChatGPT: Negative stockholders' equity of $-962.74M signals a severely impaired balance sheet. Operating margin of -77.0% and net margin of -90.5% show the business is structurally unprofitable.
What is CORZR's revenue and growth?
Core Scientific, Inc./tx reported revenue of $319.0M.
Does CORZR pay dividends?
Core Scientific, Inc./tx does not currently pay dividends.
Where can I find CORZR SEC filings?
Official SEC filings for Core Scientific, Inc./tx (CIK: 0001839341) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CORZR's EPS?
Core Scientific, Inc./tx has a diluted EPS of $-0.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CORZR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Core Scientific, Inc./tx has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CORZR stock overvalued or undervalued?
Valuation metrics for CORZR: ROE of N/A (sector avg: 12%), net margin of -90.5% (sector avg: 25%). Compare these metrics with sector averages to assess valuation.
Should I buy CORZR stock in 2026?
Our dual AI analysis gives Core Scientific, Inc./tx a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CORZR's free cash flow?
Core Scientific, Inc./tx's operating cash flow is $278.3M, with capital expenditures of $729.0M. FCF margin is -141.3%.
How does CORZR compare to other Finance stocks?
Vs Finance sector averages: Net margin -90.5% (avg: 25%), ROE N/A (avg: 12%), current ratio 1.15 (avg: 1.2).